Phase IIa trial in Duchenne Muscular Dystrophy shows vamorolone is a firs-in-
class dissociative steroidal anti-inflammatory drug.

LS Conklin; JM Damsker; EP Hoffman; WJ Jusko; PD Mavroudis; BD Schwartz; LJ Mengle-Gaw; EC Smith; JK Mah; M Guglieri; Y Nego; N Kuntz; CM McDonald; T Mar; MM Ryan; R Webster; D Castro; RS Finkel; AL Smith; LP Morgenroth; Arrieta Aa; M Shimony; M Jaros; P Shale; JM MdDall; null Hathout; K Magaraju; den Anker J van; LM Ward; A Ahmet; HR Cornish; PR Clemens

Phase IIa trial in Duchenne Muscular Dystrophy shows vamorolone is a firs-in- class dissociative steroidal anti-inflammatory drug.

LS Conklin, JM Damsker, EP Hoffman, WJ Jusko, PD Mavroudis, BD Schwartz, LJ Mengle-Gaw, EC Smith, JK Mah, M Guglieri, Y Nego, N Kuntz, CM McDonald, T Mar, MM Ryan, R Webster, D Castro, RS Finkel, AL Smith, LP MorgenrothArrieta Aa, M Shimony, M Jaros, P Shale, JM MdDall, Hathout, K Magaraju, den Anker J van, LM Ward, A Ahmet, HR Cornish, PR Clemens

Pediatrics

Research output: Contribution to journal › Article

Original language	English (US)
Journal	Pharmacologic Research
Volume	36
State	Published - 2018

Cite this

Conklin, LS., Damsker, JM., Hoffman, EP., Jusko, WJ., Mavroudis, PD., Schwartz, BD., Mengle-Gaw, LJ., Smith, EC., Mah, JK., Guglieri, M., Nego, Y., Kuntz, N., McDonald, CM., Mar, T., Ryan, MM., Webster, R., Castro, D., Finkel, RS., Smith, AL., ... Clemens, PR. (2018). Phase IIa trial in Duchenne Muscular Dystrophy shows vamorolone is a firs-in- class dissociative steroidal anti-inflammatory drug. Pharmacologic Research, 36.

@article{e4ea72e2960447179ff6decb7c783a8d,

title = "Phase IIa trial in Duchenne Muscular Dystrophy shows vamorolone is a firs-in- class dissociative steroidal anti-inflammatory drug.",

author = "LS Conklin and JM Damsker and EP Hoffman and WJ Jusko and PD Mavroudis and BD Schwartz and LJ Mengle-Gaw and EC Smith and JK Mah and M Guglieri and Y Nego and N Kuntz and CM McDonald and T Mar and MM Ryan and R Webster and D Castro and RS Finkel and AL Smith and LP Morgenroth and Arrieta Aa and M Shimony and M Jaros and P Shale and JM MdDall and Hathout and K Magaraju and van, {den Anker J} and LM Ward and A Ahmet and HR Cornish and PR Clemens",

year = "2018",

language = "English (US)",

volume = "36",

journal = "Pharmacologic Research",

}

Conklin, LS, Damsker, JM, Hoffman, EP, Jusko, WJ, Mavroudis, PD, Schwartz, BD, Mengle-Gaw, LJ, Smith, EC, Mah, JK, Guglieri, M, Nego, Y, Kuntz, N, McDonald, CM, Mar, T, Ryan, MM, Webster, R, Castro, D, Finkel, RS, Smith, AL, Morgenroth, LP, Aa, A, Shimony, M, Jaros, M, Shale, P, MdDall, JM, Hathout, Magaraju, K, van, DAJ, Ward, LM, Ahmet, A, Cornish, HR & Clemens, PR 2018, 'Phase IIa trial in Duchenne Muscular Dystrophy shows vamorolone is a firs-in- class dissociative steroidal anti-inflammatory drug.', Pharmacologic Research, vol. 36.

TY - JOUR

T1 - Phase IIa trial in Duchenne Muscular Dystrophy shows vamorolone is a firs-in- class dissociative steroidal anti-inflammatory drug.

AU - Conklin, LS

AU - Damsker, JM

AU - Hoffman, EP

AU - Jusko, WJ

AU - Mavroudis, PD

AU - Schwartz, BD

AU - Mengle-Gaw, LJ

AU - Smith, EC

AU - Mah, JK

AU - Guglieri, M

AU - Nego, Y

AU - Kuntz, N

AU - McDonald, CM

AU - Mar, T

AU - Ryan, MM

AU - Webster, R

AU - Castro, D

AU - Finkel, RS

AU - Smith, AL

AU - Morgenroth, LP

AU - Aa, Arrieta

AU - Shimony, M

AU - Jaros, M

AU - Shale, P

AU - MdDall, JM

AU - Hathout, null

AU - Magaraju, K

AU - van, den Anker J

AU - Ward, LM

AU - Ahmet, A

AU - Cornish, HR

AU - Clemens, PR

PY - 2018

Y1 - 2018

M3 - Article

VL - 36

JO - Pharmacologic Research

JF - Pharmacologic Research

ER -